Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000071.xml
Download PDF
Semin Neurol 2002; 22(3): 309-320
DOI: 10.1055/s-2002-36650
DOI: 10.1055/s-2002-36650
Epilepsy in the Elderly
Further Information
Publication History
Publication Date:
15 January 2003 (online)
ABSTRACT
The elderly are the most rapidly growing segment of our population, and onset of epilepsy is higher in this age group than in any other. With advancing age, there are changes in drug absorption, disposition, and binding. In addition, within the elderly are subgroups: (1) elderly healthy except for epilepsy (EH) and (2) elderly with multiple medical problems (EMMP). This review examines the factors that need to be considered when selecting the appropriate antiepileptic drug (AED) for an elderly person with epilepsy. Both the older and newer AEDs are reviewed.
KEYWORD
Elderly - epilepsy - antiepileptic drugs - pharmacokinetics
REFERENCES
- 1 Hauser W A. Epidemiology of seizures in the elderly. In: Rowan AJ, Ramsay RE, eds. Seizures and Epilepsy in the Elderly
Boston: Butterworth-Heinemann 1997: 7-20
MissingFormLabel
- 2 Epilepsy Foundation of America. Epilepsy, a Report to the Nation
Landover, MD: Author 1999
MissingFormLabel
- 3 Cloyd J C, Lackner T E, Leppik I E. Antiepileptics in the elderly. Pharmacoepidemiology and pharmacokinetics. Arch Fam Med . 1994; 3 589-598
- 4 Garrard J, Cloyd J C, Gross C. Factors associated with antiepileptic drug use among nursing home elderly. J Geriatr Med Sci . 2000; 55 384-392
- 5 Lackner T E, Cloyd J C, Thomas L W, Leppik K E. Antiepileptic drug use in nursing home residents: effect of age, gender, and comedication on patterns of use. Epilepsia . 1998; 39 1083-1087
- 6 Schachter S S, Cramer G W, Thompson G D, Chaponis R J, Mendelson M A, Lawhorne L. An evaluation of antiepileptic drug therapy in nursing facilities. J Am Geriatr Soc . 1998; 46 1137-1141
- 7 Dey A N. Characteristics of elderly home health care users; data from the 1994 National Home and Hospice Care Survey. Adv Data . 1996; 279 1-12
- 8 Leppik I E. Contemporary Diagnosis and Management of the Patient with Epilepsy. 5th ed. Newton, PA: Handbooks in Healthcare 2001
MissingFormLabel
- 9 Hauser W A, Hesdorffer D C. Epilepsy, Frequency, Causes and Consequences.
New York: Demos Publications 1990: 1-51
MissingFormLabel
- 10 Moor S A, Teal T W, eds. Adverse Drug Reaction Surveillance in the Geriatric Population: A Preliminary
Review. Proceedings of the Drug Information Association Workshop Geriatric Drug Use: Clinical
and Social Perspectives.
Washington, DC: Pergamon Press 1985
MissingFormLabel
- 11 Wallace S M, Verbeeck R K. Plasma protein binding of drugs in the elderly. Clin Pharmacokinet . 1987; 12 41-72
- 12 Greenblatt D J. Reduced serum albumin concentrations in the elderly: a report from the Boston Collaborative Drug Surveillance Program. J Am Geriatr Soc . 1979; 27 20-22
- 13
Rowe J W, Andres R, Tobin J D, Norris A H, Shock N W.
The effect of age on creatinine clearance in men: a cross-sectional and longitudinal
study.
J Gerontol .
1976;
31
155-163
MissingFormLabel
- 14 Verbeeck R K, Cardinal J A, Wallace S M. Effect of age and sex on the plasma binding of acidic and basic drugs. Eur J Clin Pharmacol . 1984; 27 91-97
- 15 Wynne H A, Cope L H, Mutch E, Rawlins M D, Woodhouse K W, James O F. The effect of age on liver volume and apparent liver blood flow in healthy man. Hepatology . 1989; 9 297-301
- 16 Tiula E, Neuvonen P J. Antiepileptic drugs and alpha-1 acid glycoprotein. N Engl J Med . 1982; 307 1148
- 17 Cusack B J. Drug metabolism in the elderly. J Clin Pharmacol . 1988; 28 571-576
- 18 Dawling S, Crome P. Clinical pharmacokinetic considerations in the elderly: an update. Clin Pharmacokinet . 1989; 17 236-263
- 19 Woodhouse K W, Wynne H A. Hepatic drug metabolism and aging. Br Med Bull . 1988; 15 287-296
- 20 Vestal R E, Norris A H, Tobin J D, Cohen B H, Shock N W, Andres R. Antipyrine metabolism in man: influence of age, alcohol, caffeine and smoking. Clin Pharmacol Ther . 1975; 18 425-432
- 21 Greenblatt D J, Divoll M, Harmatz J S, Shader R I. Oxazepam kinetics: effects of age and sex. J Pharmacol Exp Ther . 1980; 215 86-91
- 22 Faich G A, Dreis M, Tomita D. National adverse drug reaction surveillance 1986. Arch Intern Med . 1988; 148 785-787
- 23 Mattson R H, Cramer J A, Collins J F. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med . 1985; 313 145-151
- 24 Bauer L A, Blouin R A. Age and phenytoin kinetics in adult epileptics. Clin Pharmacol Ther . 1982; 31 301-304
- 25 Bach B, Hansen J M, Kampmann J P, Rasmussen S N, Skovsted L. Disposition of antipyrine and phenytoin correlated with age and liver volume in man. Clin Pharmacokinet . 1981; 6 389-396
- 26 Hayes M J, Langman M JS, Short A H. Changes in drug metabolism with increasing age: II. Phenytoin clearance and protein binding. Br J Clin Pharmacol . 1975; 2 73-79
- 27 Houghton G W, Richens A, Leighton M. Effects of age, height, weight and sex on serum phenytoin concentrations in epileptic patients. Br J Clin Pharmacol . 1975; 2 251-256
- 28 Lambie D C, Caird F L. Phenytoin dosage in the elderly. Age Ageing . 1977; 6 133-137
- 29 Troupin A S, Johannessen S I. Epilepsy in the elderly: a pharmacologic perspective. In: Smith DB, ed. Epilepsy: Current Approaches to Diagnosis and Treatment
New York: Raven Press 1990: 141-153
MissingFormLabel
- 30 Mooradian A D, Hernandez L, Tamai I C, Marshall C. Variability of serum phenytoin concentrations in nursing home patients. Arch Intern Med . 1989; 149 890-892
- 31 Nelson M H, Birnbaum A K, Remmel R P. Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors. Epilepsy Res . 2001; 44 71-82
- 32 Bohannon A D, Hanlon J T, Landerman R, Gold D T. Association of race and other potential risk factors with nonvertebral fractures in community-dwelling elderly women. Am J Epidemiol . 1999; 149 1002-1009
- 33 Bauer L A, Davis R, Wilensky A. Valproic acid clearance: unbound fraction and diurnal variation in young and elderly adults. Clin Pharmacol Ther . 1985; 37 697-700
- 34 Bryson S M, Verma N, Scott P JW. Pharmacokinetics of valproic acid in young and elderly subjects. Br J Clin Pharmacol . 1983; 16 104-105
- 35 Perucca E, Grimaldi R, Gatti G, Pirracchio S, Crema F, Frigo G M. Pharmacokinetics of valproic acid in the elderly. Br J Clin Pharmacol . 1984; 17 665-669
- 36 Graves N M. Felbamate. Ann Pharmacother . 1993; 27 1073-1081
- 37 Richens A. Clinical pharmacokinetics of gabapentin. In: Chadwick D, ed. New Trends in Epilepsy Management: The Role of Gabapentin
London: Royal Society of Medicine Services 1993: 41-46
MissingFormLabel
- 38 Peck A W. Clinical pharmacology of lamotrigine. Epilepsia . 1991; 32 (suppl 2) S9-S12
- 39 Posner J, Holdich T, Crome P. Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers. J Pharm Med . 1991; 1 121-128
- 40 Hussein Z, Posner J. Population pharmacokinetics of lamo-trigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol . 1997; 43 457-465
- 41 Yuen A W, Land G, Weatherley B C, Peck A W. Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol . 1992; 33 511-513
- 42 Sachdeo R C, Sachdeo S K, Walker S A, Kramer L D, Nayak R K, Doose D R. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia . 1996; 37 774-780
- 43 Levy R H, Bishop F, Streeter A J. Explanation and prediction of drug interactions with topiramate using a CYP450 inhibition
spectrum. In: Cereghino J, ed. Annual Meeting of the American Epilepsy Society
Baltimore: Lippincott-Raven 1995: 47
MissingFormLabel
- 44 Faigle J W, Menge G P. Metabolic characteristics of oxcarbazepine (Trileptal) and their beneficial implications for enzyme induction and drug interactions. Behav Neurol . 1990; 3 21-30
- 45 van Heiningen N P, Eve M D, Oosterhuis B. The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine. Clin Pharmacol Ther . 1991; 50 410-419
- 46 Klosterskov J P, Saano V, Harin P, Svenstrup B, Nenge G. Possible interaction between oxcarbazepine and an oral contraceptive. Epilepsia . 1992; 33 1149-1152
- 47 Zaccara G, Gangemi P F, Bendoni L, Menge G P, Schwabe S, Monza G C. Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine. Ther Drug Monit . 1993; 15 39-42
- 48 Hossain M, Sallas W, Gasparini M. Drug-drug interaction profile of oxcarbazepine in children and adults (abstract). Neurology . 1999; 52 (suppl 2) A525
- 49 Isojarvi J IT, Huuskonen U EJ, Pakarinen A J, Vuolteenaho O, Myllyla V V. The regulation of serum sodium after replacing carbamazepine with oxcarbazepine. Epilepsia . 2001; 42 741-745
- 50 Leppik I E. The place of levetiracetam in the treatment of epilepsy. Epilepsia . 2001; 42 44-45
- 51 Patsalos P N, Sander J W. Newer antiepileptic drugs. Towards an improved risk-benefit ratio. Drug Saf . 1994; 11 37-67
- 52 French J. Use of levetiracetam in special populations. Epilepsia . 2001; 42 40-43
- 53 Cook P J, Flanagan R, James I M. Diazepam tolerance: effect of age, regular sedation and alcohol. Br Med J . 1984; 289 351-353
- 54 Hansten P D, Horn J R. Drug Interactions: A Clinical Perspective and Analysis of Current Developments.
Vancouver, WA: Applied Therapeutics Inc 1993: 331-371
MissingFormLabel
- 55 Nation R L, Evans A M, Milne R W. Pharmacokinetic drug interactions with phenytoin, I, II. Clin Pharmacokinet . 1990; 18 37-150
- 56 Bollini P, Riva R, Albani F. Decreased phenytoin levels during antineoplastic therapy: a case report. Epilepsia . 1983; 24 75-78
- 57 Neef C, de Voogd-van den Straaten I. An interaction between cytostatic and anticonvulsant drugs. Clin Pharmacol Ther . 1988; 43 372-375
- 58 Haley C J, Nelson J. Phenytoin-enteral feeding interaction. Ann Pharmacother . 1989; 23 796-798
- 59 Sandor P, Sellers E M, Dumbrell M, Khouse V. Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics. Clin Pharmacol Ther . 1981; 30 390-397
- 60 Cold J A, Wells B G, Froemming J H. Seizure activity associated with antipsychotic therapy. Ann Pharmacother . 1990; 24 601-606
- 61 Bender A D, Post A, Meier J P, Higson J E, Reichard Jr G. Plasma protein binding of drugs as a function of age in adult human subjects. J Pharm Sci . 1975; 64 1711-1713
- 62 Drinka P J, Miller J, Voeks S K, Hamel P. Phenytoin binding in a nursing home. J Geriatr Drug Ther . 1988; 3 73-82
- 63 Eadie M J, Lander C M, Hooper W D, Tyrer J H. Factors influencing plasma phenobarbital levels in epileptic patients. Br J Clin Pharmacol . 1977; 4 41-47
- 64 Edwards G B, Culberton V L, Anresen G B, Rhodes P J. Free phenytoin concentrations in geriatrics. J Geriatr Drug Ther . 1988; 3 97-102
- 65 Martines C, Gatti G, Sasso E, Calzetti S, Perucca E. The disposition of primidone in elderly patients. Br J Clin Pharmacol . 1990; 30 607-611
- 66 Morselli P L. Carbamazepine: Absorption, Distribution and Excretion.
Antiepileptic Drugs. 3rd ed. New York: Raven Press 1989: 473-490
MissingFormLabel
- 67 Patterson M, Heazelwood R, Smithhurst B, Eadie M J. Plasma protein binding of phenytoin in the aged: in-vivo studies. Br J Clin Pharmacol . 1982; 13 423-425
- 68 Sherwin A L, Loynd J S, Bock G W, Sokolowski C D. Effects of age, sex, obesity, and pregnancy on plasma diphenylhydantoin levels. Epilepsia . 1974; 15 507-521
- 69 Umstead G S, Morales M, McKercher P l. Comparison of total, free, and salivary phenytoin concentrations in geriatric patients. Clin Pharm . 1986; 5 59-62